Indevus Pharma Raises $105M in Debt Sale

Xconomy Boston — 

Indevus Pharmaceuticals (NASDAQ:INDEV), a Lexington, MA, specialty pharmaceutical firm, announced it has raised $105 million in a private placement of non-recourse notes. The company said the sale of the notes, which are secured by royalties from its overactive bladder drug Sanctura, is intended to retire existing debt due next year and fund operations into calendar 2010.